Hu Zhou

机构：Henan Cancer Hospital

发表论文 21 篇 · 总被引 75 次 · h-index 4

代表论文

• A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera (2023 · Experimental Hematology and Oncology · 被引 34)
• Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b (2024 · British Journal of Haematology · 被引 17)
• Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial (2025 · BMJ · 被引 6)
• Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study (2024 · Blood Cancer Journal · 被引 5)
• Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera (2025 · Blood Advances · 被引 3)
• Chinese guidance for the clinical application of adeno-associated virus vector-based gene therapy for hemophilia B (2025) (2025 · Blood Science · 被引 3)